Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland, and UK.

Galderma announced it has received filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland, and the UK via the Access Consortium framework. The US FDA and EMA also accepted filing submissions in February 2024 for the treatment of prurigo nodularis and atopic dermatitis. Further submissions are ongoing in additional countries.